In this retrospective study involving Chinese patients with resected stage III melanoma, PD-1 inhibitors not only significantly prolonged the RFS but also contributed to prolonging DMFS compared with conventional therapy (IFN+OBS). The gene discussed is PDCD1; the disease is melanoma.